https://charts.traderzeitung.de/phases/US6031701013
string(1458) "{"isin":"US6031701013","name":"Mineralys Therapeutics Inc","stock_id_xnas":29670197,"stock_id_xnys":null,"generated_at":"2026-08-27 05:02:00","days":[{"date":"2026-08-24","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":25.64,"close_at":"2026-08-24 15:26:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":25.3,"close_at":"2026-08-24 21:59:00","complete":true,"perf_pct":-1.3261},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-25","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":25.3,"close_at":"2026-08-25 13:35:00","complete":true,"perf_pct":0},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":26.347,"close_at":"2026-08-25 21:59:00","complete":true,"perf_pct":4.1383},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-26","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":26.5,"close_at":"2026-08-26 13:53:00","complete":true,"perf_pct":0.5807},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":25.88,"close_at":"2026-08-26 21:59:00","complete":true,"perf_pct":-2.3396},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Mineralys Therapeutics Aktie News & Nachrichten
Trading-Room

Mineralys Therapeutics Aktie News & Nachrichten

[WKN: A3D5YN | Symbol: MLYS]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Mineralys Therapeutics

Mineralys Therapeutics: Therapieansatz bestätigt durch AstraZeneca-Daten

Mineralys Therapeutics ist ein Biotechnologieunternehmen aus Pennsylvania, das neue Therapien gegen Bluthochdruck...

  • ‹
  • 1
  • ›
Mineralys Therapeutics Nachrichtenticker öffnen
MT Newswires 11.08.2026 22:47 Uhr

Mineralys Therapeutics verzeichnet größeren Verlust im Q2

04:46 PM EDT, 11.08.2026 (MT Newswires) -- Mineralys Therapeutics (MLYS) meldete am späten Dienstag einen Verlust im Q2 von 2,85 USD je verwässerter A

MT Newswires 11.08.2026 22:30 Uhr

-- Earnings Flash (MLYS) Mineralys Therapeutics verzeichnet Q2-Verlust von 2,85 $, verglichen mit FactSet-Schätzung von 0,55 $ Verlust

04:29 PM EDT, 11.08.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 01.07.2026 10:11 Uhr

Mineralys Therapeutics Insider verkaufte Aktien im Wert von $2.696.322, laut einer aktuellen SEC-Einreichung

04:10 AM EDT, 07/01/2026 (MT Newswires) -- Eric Warren, Chief Commercial Officer, verkaufte am 26. Juni 2026 104.124 Aktien von Mineralys Therapeutics

MT Newswires 01.07.2026 10:11 Uhr

Mineralys Therapeutics Insider verkaufte Aktien im Wert von $1.960.601, laut einer aktuellen SEC-Einreichung

04:10 AM EDT, 07/01/2026 (MT Newswires) -- Jon Congleton, Direktor, Chief Executive Officer, verkaufte am 30. Juni 2026 75.000 Aktien von Mineralys Th

MT Newswires 03.06.2026 13:36 Uhr

Mineralys preist $150 Millionen Aktienangebot ein, kauft Lorundrostat-Lizenzgebührenverpflichtungen zurück

07:35 AM EDT, 06/03/2026 (MT Newswires) -- Mineralys Therapeutics (MLYS) preiste ein garantiertes Angebot von etwa 5,7 Millionen Aktien zu $26,50 pro